Controlled medication - Anti- IL5

Question 1

Mepolizumab (Nucala®)
Dosage form

Answer 1

Injection

Question 2

Mepolizumab (Nucala®)
Dosing

Answer 2

Dosing in 5-11-year-olds
- 40mg subQ Q4 weeks
Adult dosing
- 100mg SubQ Q4 weeks

Question 3

Reslizumab (Cinqair®)
Dosage form

Answer 3

Normal saline solution injection

Question 4

Reslizumab (Cinqair®)
Dosing

Answer 4

Adult dosing
- 3mg/kg IV once q4 weeks

Question 5

Benralizumab (Fasenra®)
Dosage form

Answer 5

auto-injector
pre filled syringe

Question 6

Benralizumab (Fasenra®)
Dosing

Answer 6

Adult Dosing
- 30 mg subcutaneously every 4 weeks for 3 doses, then 30mg subcutaneously every 8 weeks

Question 7

Benralizumab (Fasenra®)
Adverse effect

Answer 7

• AE: injection site reactions, antibody development, headache, pharyngitis, fever
• Precaution: anaphylaxis
• Available as an in-clinic or at-home injection
• Indicated for add-on maintenance treatment of
  severe asthma in adults and children ≥12 years of
  age with an eosinophilic phenotype
• Acts on IL-5 receptors while others act on IL-5

Question 8

Reslizumab (Cinqair®)

Answer 8

AE: injection site reactions, myalgias, increased creatinine phosphokinase
* Boxed warning: anaphylaxis, malignancies
* Monitor for anaphylaxis before and after injection * Indicated for add-on maintenance treatment of
patients with severe asthma with an eosinophilic phenotype

Question 9

Mepolizumab (Nucala®)

Answer 9

AE: headache, injection site reactions, arthralgias,
Herpes Zoster infection
* Precaution: anaphylaxis
* Available as an in-clinic or at-home injection
* Monitor for anaphylaxis before and after injection
* Indicated for add-on maintenance treatment of
patients with severe asthma with an eosinophilic phenotype